- Home
- APRE vs DRCT Comparison
APRE vs DRCT Comparison
Compare APRE & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- DRCT
- Stock Information
- Founded
- APRE 2006
- DRCT 2018
- Country
- APRE United States
- DRCT United States
- Employees
- APRE N/A
- DRCT N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- DRCT Computer Software: Programming Data Processing
- Sector
- APRE Health Care
- DRCT Technology
- Exchange
- APRE Nasdaq
- DRCT Nasdaq
- Market Cap
- APRE 8.3M
- DRCT 8.8M
- IPO Year
- APRE 2019
- DRCT 2022
- Fundamental
- Price
- APRE $1.51
- DRCT $0.37
- Analyst Decision
- APRE Strong Buy
- DRCT Strong Buy
- Analyst Count
- APRE 1
- DRCT 1
- Target Price
- APRE $20.00
- DRCT $6.00
- AVG Volume (30 Days)
- APRE 50.3K
- DRCT 6.4M
- Earning Date
- APRE 11-06-2025
- DRCT 11-11-2025
- Dividend Yield
- APRE N/A
- DRCT N/A
- EPS Growth
- APRE N/A
- DRCT N/A
- EPS
- APRE N/A
- DRCT N/A
- Revenue
- APRE $841,012.00
- DRCT $36,459,000.00
- Revenue This Year
- APRE N/A
- DRCT $16.81
- Revenue Next Year
- APRE N/A
- DRCT $35.28
- P/E Ratio
- APRE N/A
- DRCT N/A
- Revenue Growth
- APRE N/A
- DRCT N/A
- 52 Week Low
- APRE $1.37
- DRCT $0.28
- 52 Week High
- APRE $5.01
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- APRE 51.04
- DRCT 50.31
- Support Level
- APRE $1.40
- DRCT $0.28
- Resistance Level
- APRE $1.53
- DRCT $0.50
- Average True Range (ATR)
- APRE 0.08
- DRCT 0.06
- MACD
- APRE 0.01
- DRCT 0.01
- Stochastic Oscillator
- APRE 67.77
- DRCT 36.61
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.